Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
Identifieur interne : 000F36 ( Main/Exploration ); précédent : 000F35; suivant : 000F37Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
Auteurs : Karen L. Eskow Jaunarajs [États-Unis] ; David G. Standaert [États-Unis] ; Tacey X. Viegas [États-Unis] ; Michael D. Bentley [États-Unis] ; Zhihao Fang [États-Unis] ; Bekir Dizman [États-Unis] ; Kunsang Yoon [États-Unis] ; Rebecca Weimer [États-Unis] ; Paula Ravenscroft [Canada] ; Tom H. Johnston [Canada] ; Michael P. Hill [Canada] ; Jonathan M. Brotchie [Canada] ; Randall W. Moreadith [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2013-10.
Abstract
Currently available dopaminergic drugs such as levodopa and dopamine (DA) receptor agonists impart considerable improvement in Parkinson's disease (PD) motor symptoms but often lead to significant motor complications including “wearing‐off” and dyskinesia. Such complications are believed to stem from the pulsatile nature of dopaminergic stimulation with these agents. Continuous dopaminergic drug delivery using polyoxazoline (POZ) polymer conjugation may improve motor symptoms, while avoiding development of side effects. The purposes of the current study are to characterize the in vitro and in vivo pharmacokinetics of POZ conjugation of a U.S. Food and Drug Administration (FDA)‐approved DA agonist, rotigotine, and to evaluate their effects in an established rat model of PD. After determination of release profiles of several POZ‐conjugated constructs (“fast”: SER‐212; “moderate”: SER‐213; and “slow”: SER‐214) using in vitro hydrolysis, normal male Sprague‐Dawley rats were used for determination of the pharmacokinetic profile of both acute and chronic exposure. Finally, a separate group of rats was rendered hemiparkinsonian using intracranial 6‐hydroxydopamine (6‐OHDA) infusions, treated acutely with POZ‐rotigotine, and assessed for rotational behavior and antiparkinsonian benefit using the cylinder test. POZ‐rotigotine formulations SER‐213 and SER‐214 led to substantial pharmacokinetic improvement compared to unconjugated rotigotine. In addition, SER‐214 led to antiparkinsonian effects in DA‐lesioned rats that persisted up to 5 days posttreatment. Repeated weekly dose administration of SER‐214 to normal rats for up to 12 weeks demonstrated highly reproducible pharmacokinetic profiles. The continuous dopaminergic stimulation profile afforded by SER‐214 could represent a significant advance in the treatment of PD, with potential to be a viable, once‐per‐week therapy for PD patients.
Url:
DOI: 10.1002/mds.25625
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000604
- to stream Istex, to step Curation: 000604
- to stream Istex, to step Checkpoint: 000054
- to stream Main, to step Merge: 000F48
- to stream Main, to step Curation: 000F36
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit</title><author><name sortKey="Eskow Jaunarajs, Karen L" sort="Eskow Jaunarajs, Karen L" uniqKey="Eskow Jaunarajs K" first="Karen L." last="Eskow Jaunarajs">Karen L. Eskow Jaunarajs</name></author><author><name sortKey="Standaert, David G" sort="Standaert, David G" uniqKey="Standaert D" first="David G." last="Standaert">David G. Standaert</name></author><author><name sortKey="Viegas, Tacey X" sort="Viegas, Tacey X" uniqKey="Viegas T" first="Tacey X." last="Viegas">Tacey X. Viegas</name></author><author><name sortKey="Bentley, Michael D" sort="Bentley, Michael D" uniqKey="Bentley M" first="Michael D." last="Bentley">Michael D. Bentley</name></author><author><name sortKey="Fang, Zhihao" sort="Fang, Zhihao" uniqKey="Fang Z" first="Zhihao" last="Fang">Zhihao Fang</name></author><author><name sortKey="Dizman, Bekir" sort="Dizman, Bekir" uniqKey="Dizman B" first="Bekir" last="Dizman">Bekir Dizman</name></author><author><name sortKey="Yoon, Kunsang" sort="Yoon, Kunsang" uniqKey="Yoon K" first="Kunsang" last="Yoon">Kunsang Yoon</name></author><author><name sortKey="Weimer, Rebecca" sort="Weimer, Rebecca" uniqKey="Weimer R" first="Rebecca" last="Weimer">Rebecca Weimer</name></author><author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name></author><author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Moreadith, Randall W" sort="Moreadith, Randall W" uniqKey="Moreadith R" first="Randall W." last="Moreadith">Randall W. Moreadith</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4F7894514D755826E1536555A418DCCAF9D2765E</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/mds.25625</idno><idno type="url">https://api-v5.istex.fr/document/4F7894514D755826E1536555A418DCCAF9D2765E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000604</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000604</idno><idno type="wicri:Area/Istex/Curation">000604</idno><idno type="wicri:Area/Istex/Checkpoint">000054</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000054</idno><idno type="wicri:doubleKey">0885-3185:2013:Eskow Jaunarajs K:rotigotine:polyoxazoline:conjugate</idno><idno type="wicri:Area/Main/Merge">000F48</idno><idno type="wicri:Area/Main/Curation">000F36</idno><idno type="wicri:Area/Main/Exploration">000F36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit</title><author><name sortKey="Eskow Jaunarajs, Karen L" sort="Eskow Jaunarajs, Karen L" uniqKey="Eskow Jaunarajs K" first="Karen L." last="Eskow Jaunarajs">Karen L. Eskow Jaunarajs</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation></author><author><name sortKey="Standaert, David G" sort="Standaert, David G" uniqKey="Standaert D" first="David G." last="Standaert">David G. Standaert</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author><author><name sortKey="Viegas, Tacey X" sort="Viegas, Tacey X" uniqKey="Viegas T" first="Tacey X." last="Viegas">Tacey X. Viegas</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea><wicri:noRegion>Huntsville</wicri:noRegion></affiliation></author><author><name sortKey="Bentley, Michael D" sort="Bentley, Michael D" uniqKey="Bentley M" first="Michael D." last="Bentley">Michael D. Bentley</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea><wicri:noRegion>Huntsville</wicri:noRegion></affiliation></author><author><name sortKey="Fang, Zhihao" sort="Fang, Zhihao" uniqKey="Fang Z" first="Zhihao" last="Fang">Zhihao Fang</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea><wicri:noRegion>Huntsville</wicri:noRegion></affiliation></author><author><name sortKey="Dizman, Bekir" sort="Dizman, Bekir" uniqKey="Dizman B" first="Bekir" last="Dizman">Bekir Dizman</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea><wicri:noRegion>Huntsville</wicri:noRegion></affiliation></author><author><name sortKey="Yoon, Kunsang" sort="Yoon, Kunsang" uniqKey="Yoon K" first="Kunsang" last="Yoon">Kunsang Yoon</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea><wicri:noRegion>Huntsville</wicri:noRegion></affiliation></author><author><name sortKey="Weimer, Rebecca" sort="Weimer, Rebecca" uniqKey="Weimer R" first="Rebecca" last="Weimer">Rebecca Weimer</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea><wicri:noRegion>Huntsville</wicri:noRegion></affiliation></author><author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Moreadith, Randall W" sort="Moreadith, Randall W" uniqKey="Moreadith R" first="Randall W." last="Moreadith">Randall W. Moreadith</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea><wicri:noRegion>Huntsville</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-10">2013-10</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1675">1675</biblScope><biblScope unit="page" to="1682">1682</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4F7894514D755826E1536555A418DCCAF9D2765E</idno><idno type="DOI">10.1002/mds.25625</idno><idno type="ArticleID">MDS25625</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Currently available dopaminergic drugs such as levodopa and dopamine (DA) receptor agonists impart considerable improvement in Parkinson's disease (PD) motor symptoms but often lead to significant motor complications including “wearing‐off” and dyskinesia. Such complications are believed to stem from the pulsatile nature of dopaminergic stimulation with these agents. Continuous dopaminergic drug delivery using polyoxazoline (POZ) polymer conjugation may improve motor symptoms, while avoiding development of side effects. The purposes of the current study are to characterize the in vitro and in vivo pharmacokinetics of POZ conjugation of a U.S. Food and Drug Administration (FDA)‐approved DA agonist, rotigotine, and to evaluate their effects in an established rat model of PD. After determination of release profiles of several POZ‐conjugated constructs (“fast”: SER‐212; “moderate”: SER‐213; and “slow”: SER‐214) using in vitro hydrolysis, normal male Sprague‐Dawley rats were used for determination of the pharmacokinetic profile of both acute and chronic exposure. Finally, a separate group of rats was rendered hemiparkinsonian using intracranial 6‐hydroxydopamine (6‐OHDA) infusions, treated acutely with POZ‐rotigotine, and assessed for rotational behavior and antiparkinsonian benefit using the cylinder test. POZ‐rotigotine formulations SER‐213 and SER‐214 led to substantial pharmacokinetic improvement compared to unconjugated rotigotine. In addition, SER‐214 led to antiparkinsonian effects in DA‐lesioned rats that persisted up to 5 days posttreatment. Repeated weekly dose administration of SER‐214 to normal rats for up to 12 weeks demonstrated highly reproducible pharmacokinetic profiles. The continuous dopaminergic stimulation profile afforded by SER‐214 could represent a significant advance in the treatment of PD, with potential to be a viable, once‐per‐week therapy for PD patients.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Midlands de l'Ouest</li></region><settlement><li>Birmingham</li></settlement></list><tree><country name="États-Unis"><region name="Angleterre"><name sortKey="Eskow Jaunarajs, Karen L" sort="Eskow Jaunarajs, Karen L" uniqKey="Eskow Jaunarajs K" first="Karen L." last="Eskow Jaunarajs">Karen L. Eskow Jaunarajs</name></region><name sortKey="Bentley, Michael D" sort="Bentley, Michael D" uniqKey="Bentley M" first="Michael D." last="Bentley">Michael D. Bentley</name><name sortKey="Dizman, Bekir" sort="Dizman, Bekir" uniqKey="Dizman B" first="Bekir" last="Dizman">Bekir Dizman</name><name sortKey="Fang, Zhihao" sort="Fang, Zhihao" uniqKey="Fang Z" first="Zhihao" last="Fang">Zhihao Fang</name><name sortKey="Moreadith, Randall W" sort="Moreadith, Randall W" uniqKey="Moreadith R" first="Randall W." last="Moreadith">Randall W. Moreadith</name><name sortKey="Standaert, David G" sort="Standaert, David G" uniqKey="Standaert D" first="David G." last="Standaert">David G. Standaert</name><name sortKey="Standaert, David G" sort="Standaert, David G" uniqKey="Standaert D" first="David G." last="Standaert">David G. Standaert</name><name sortKey="Viegas, Tacey X" sort="Viegas, Tacey X" uniqKey="Viegas T" first="Tacey X." last="Viegas">Tacey X. Viegas</name><name sortKey="Weimer, Rebecca" sort="Weimer, Rebecca" uniqKey="Weimer R" first="Rebecca" last="Weimer">Rebecca Weimer</name><name sortKey="Yoon, Kunsang" sort="Yoon, Kunsang" uniqKey="Yoon K" first="Kunsang" last="Yoon">Kunsang Yoon</name></country><country name="Canada"><noRegion><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name></noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4F7894514D755826E1536555A418DCCAF9D2765E
|texte= Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
}}
| This area was generated with Dilib version V0.6.29. |  |